Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Key Terms

cataracts medical

A cataract is a clouding of the eye’s natural lens that blurs vision, much like a fogged-up camera lens or window. For investors, cataracts matter because they are common with aging and drive predictable demand for surgeries, lenses, medical devices and related drugs and services, affecting revenue and growth prospects for healthcare providers, device makers and companies serving an older population.

glaucoma medical

Glaucoma is a group of eye diseases that slowly damage the optic nerve, often because fluid buildup raises pressure inside the eye, and can lead to permanent vision loss if untreated. For investors, glaucoma matters because it creates sustained demand for medications, surgical devices, diagnostics and follow-up care; breakthroughs or approvals can drive sales and market value much like fixing a clogged drain prevents damage to a house’s wiring.

retinal diseases medical

Retinal diseases are conditions that damage the retina, the light-sensitive layer at the back of the eye that works like a camera sensor to convert images into signals the brain can read. Investors care because these conditions drive demand for drugs, surgical devices, and diagnostic tests; breakthroughs, approvals, or setbacks can change a company’s future sales prospects, regulatory risk and patient access, much like a new technology reshaping a market.

refractive errors medical

Refractive errors are common vision problems that occur when the eye does not bend (refract) light correctly, leaving images out of focus—like a camera lens that needs adjusting. Examples include nearsightedness, farsightedness, astigmatism and age‑related focusing loss; they matter to investors because they create steady demand for eyeglasses, contact lenses, diagnostic services, corrective surgery and related products, driving predictable revenue and healthcare spending.

12/30/2025 - 04:30 PM

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST.

A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Connect with us on
Facebook
LinkedIn